| Dr Rasheel Chowdhary, MD | |
|
5979 S Fashion Blvd, Murray, UT 84107-7364 | |
| (801) 263-2370 | |
| Not Available |
| Full Name | Dr Rasheel Chowdhary |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 5979 S Fashion Blvd, Murray, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467656264 | NPI | - | NPPES |
| 1467656264 | Medicaid | UT |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital Sweetwater County | Rock springs, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Hospital Of Sweetwater County | 0244124550 | 49 |
News Archive
Liver damage caused by medicinal drugs is one of the most common reasons for liver failure and liver transplants in the Western world. Nevertheless, it is difficult to predict which active ingredients will turn out to be toxic for the organ. Oftentimes the problems are not discovered until the drug is already on the market. Prof. Dr. Jens Timmer, Freiburg physicist and Director of the FRIAS School of Life Sciences - LifeNet, is a project partner in a consortium that wants to solve this problem.
Cardiac experts at Rush University Medical Center are studying a new, minimally invasive procedure to treat leaky heart valves. Instead of open heart surgery, patients will undergo a less complex catheter-based procedure to treat mitral regurgitation, a serious heart disorder where blood leaks backwards toward the lungs with each heart beat.
MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.
More powerful gene-sequencing tools have increasingly been uncovering disease secrets in DNA within the cell nucleus. Now a research team is expanding those rapid next-generation sequencing tests to analyze a separate source of DNA—within the genes inside mitochondria, cellular power plants that, when abnormal, contribute to complex, multisystem diseases.
› Verified 3 days ago
| Entity Name | Memorial Hospital Of Sweetwater County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558361949 PECOS PAC ID: 0244124550 Enrollment ID: O20040209000957 |
News Archive
Liver damage caused by medicinal drugs is one of the most common reasons for liver failure and liver transplants in the Western world. Nevertheless, it is difficult to predict which active ingredients will turn out to be toxic for the organ. Oftentimes the problems are not discovered until the drug is already on the market. Prof. Dr. Jens Timmer, Freiburg physicist and Director of the FRIAS School of Life Sciences - LifeNet, is a project partner in a consortium that wants to solve this problem.
Cardiac experts at Rush University Medical Center are studying a new, minimally invasive procedure to treat leaky heart valves. Instead of open heart surgery, patients will undergo a less complex catheter-based procedure to treat mitral regurgitation, a serious heart disorder where blood leaks backwards toward the lungs with each heart beat.
MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.
More powerful gene-sequencing tools have increasingly been uncovering disease secrets in DNA within the cell nucleus. Now a research team is expanding those rapid next-generation sequencing tests to analyze a separate source of DNA—within the genes inside mitochondria, cellular power plants that, when abnormal, contribute to complex, multisystem diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rasheel Chowdhary, MD 5979 S Fashion Blvd, Murray, UT 84107-7364 Ph: (801) 263-2370 | Dr Rasheel Chowdhary, MD 5979 S Fashion Blvd, Murray, UT 84107-7364 Ph: (801) 263-2370 |
News Archive
Liver damage caused by medicinal drugs is one of the most common reasons for liver failure and liver transplants in the Western world. Nevertheless, it is difficult to predict which active ingredients will turn out to be toxic for the organ. Oftentimes the problems are not discovered until the drug is already on the market. Prof. Dr. Jens Timmer, Freiburg physicist and Director of the FRIAS School of Life Sciences - LifeNet, is a project partner in a consortium that wants to solve this problem.
Cardiac experts at Rush University Medical Center are studying a new, minimally invasive procedure to treat leaky heart valves. Instead of open heart surgery, patients will undergo a less complex catheter-based procedure to treat mitral regurgitation, a serious heart disorder where blood leaks backwards toward the lungs with each heart beat.
MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.
More powerful gene-sequencing tools have increasingly been uncovering disease secrets in DNA within the cell nucleus. Now a research team is expanding those rapid next-generation sequencing tests to analyze a separate source of DNA—within the genes inside mitochondria, cellular power plants that, when abnormal, contribute to complex, multisystem diseases.
› Verified 3 days ago
Bogdan Ciprian Anea, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: Intermountain Kidney Services Clinic, 5169 South Cottonwood Street, Suite 320, Murray, UT 84107 Phone: 801-507-2531 Fax: 801-507-2597 | |
E Dennis Genebach, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5801 Fashion Blvd, Murray, UT 84107 Phone: 801-314-4544 | |
Dr. Samuel Morris Brown, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5121 S Cottonwood St, Murray, UT 84107 Phone: 801-507-6415 | |
Dr. Jamie Lynn Rebman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5121 Cottonwood Rd, Suite 610, Murray, UT 84107 Phone: 801-507-3630 Fax: 801-507-3630 | |
Dr. Kia Afshar, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5169 S Cottonwood St Ste 520, Murray, UT 84107 Phone: 801-507-4701 | |
Rachel Elizabeth Hu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5171 S Cottonwood St Ste 610, Murray, UT 84107 Phone: 801-507-3900 Fax: 801-507-3640 | |
Caroline Nebhan, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5171 S Cottonwood St Ste 610, Murray, UT 84107 Phone: 801-507-3630 |